Cargando…

Safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis

Cell therapy is a promising alternative treatment approach currently under study for osteoarthritis (OA), the most common chronic musculoskeletal disease. However, the mesenchymal stem cells (MSCs) used in cell therapy to treat OA are usually expanded in vitro to obtain sufficient numbers for transp...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Mitsuru, Ozeki, Nobutake, Sekiya, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society for Regenerative Medicine 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234008/
https://www.ncbi.nlm.nih.gov/pubmed/35785042
http://dx.doi.org/10.1016/j.reth.2022.06.003
_version_ 1784735950889287680
author Mizuno, Mitsuru
Ozeki, Nobutake
Sekiya, Ichiro
author_facet Mizuno, Mitsuru
Ozeki, Nobutake
Sekiya, Ichiro
author_sort Mizuno, Mitsuru
collection PubMed
description Cell therapy is a promising alternative treatment approach currently under study for osteoarthritis (OA), the most common chronic musculoskeletal disease. However, the mesenchymal stem cells (MSCs) used in cell therapy to treat OA are usually expanded in vitro to obtain sufficient numbers for transplantation, and their safety has not been fully assessed from multiple perspectives. Analysis of karyotypic abnormalities, in particular, is important to ensure the safety of cells; however, chromosomal mutations may also occur during the cell-expansion process. In addition, there have been many reports showing chromosome abnormalities, mainly trisomy 7, in the cartilage and synovium of patients with OA as well as in normal tissues. The suitability of cells with these karyotypic abnormalities as cells for cell therapy has not been evaluated. Recently, we assessed the safety of using cells with trisomy 7 from the osteoarthritic joint of a patient for transplantation, and we followed up with the patient for 5 years. This study showed analysis for copy number variant and whole-genome sequencing, compared with blood DNA from the same patient. We did not find any abnormalities in the genes regardless of trisomy 7. No side effects were observed for at least 5 years in the human clinical study. This suggests that the transplantation of cultured cells with trisomy 7 isolated from an osteoarthritic joint and transplanted into the osteoarthritic joints of the same person is not expected to cause serious adverse events. However, it is unclear what problems may arise in the case of allogeneic transplantation. Different types of risks will also exist depending on other transplantation routes, such as localization to the knee-joint only or circulation inflow and lung entrapment. In addition, since the cause of trisomy 7 occurrence remains unclear, it is necessary to clarify the mechanism of trisomy 7 in OA to perform cell therapy for OA patients in a safe manner.
format Online
Article
Text
id pubmed-9234008
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Japanese Society for Regenerative Medicine
record_format MEDLINE/PubMed
spelling pubmed-92340082022-07-01 Safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis Mizuno, Mitsuru Ozeki, Nobutake Sekiya, Ichiro Regen Ther Review Cell therapy is a promising alternative treatment approach currently under study for osteoarthritis (OA), the most common chronic musculoskeletal disease. However, the mesenchymal stem cells (MSCs) used in cell therapy to treat OA are usually expanded in vitro to obtain sufficient numbers for transplantation, and their safety has not been fully assessed from multiple perspectives. Analysis of karyotypic abnormalities, in particular, is important to ensure the safety of cells; however, chromosomal mutations may also occur during the cell-expansion process. In addition, there have been many reports showing chromosome abnormalities, mainly trisomy 7, in the cartilage and synovium of patients with OA as well as in normal tissues. The suitability of cells with these karyotypic abnormalities as cells for cell therapy has not been evaluated. Recently, we assessed the safety of using cells with trisomy 7 from the osteoarthritic joint of a patient for transplantation, and we followed up with the patient for 5 years. This study showed analysis for copy number variant and whole-genome sequencing, compared with blood DNA from the same patient. We did not find any abnormalities in the genes regardless of trisomy 7. No side effects were observed for at least 5 years in the human clinical study. This suggests that the transplantation of cultured cells with trisomy 7 isolated from an osteoarthritic joint and transplanted into the osteoarthritic joints of the same person is not expected to cause serious adverse events. However, it is unclear what problems may arise in the case of allogeneic transplantation. Different types of risks will also exist depending on other transplantation routes, such as localization to the knee-joint only or circulation inflow and lung entrapment. In addition, since the cause of trisomy 7 occurrence remains unclear, it is necessary to clarify the mechanism of trisomy 7 in OA to perform cell therapy for OA patients in a safe manner. Japanese Society for Regenerative Medicine 2022-06-17 /pmc/articles/PMC9234008/ /pubmed/35785042 http://dx.doi.org/10.1016/j.reth.2022.06.003 Text en © 2022 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Mizuno, Mitsuru
Ozeki, Nobutake
Sekiya, Ichiro
Safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis
title Safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis
title_full Safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis
title_fullStr Safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis
title_full_unstemmed Safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis
title_short Safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis
title_sort safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234008/
https://www.ncbi.nlm.nih.gov/pubmed/35785042
http://dx.doi.org/10.1016/j.reth.2022.06.003
work_keys_str_mv AT mizunomitsuru safetyofusingculturedcellswithtrisomy7incelltherapyfortreatingosteoarthritis
AT ozekinobutake safetyofusingculturedcellswithtrisomy7incelltherapyfortreatingosteoarthritis
AT sekiyaichiro safetyofusingculturedcellswithtrisomy7incelltherapyfortreatingosteoarthritis